APIDRA

LOE Approaching

insulin glulisine

BLAINTRAVENOUS, SUBCUTANEOUSINJECTABLE
Approved
Apr 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
85

Mechanism of Action

analogs, including insulin glulisine. Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis and enhance protein synthesis.

Pharmacologic Class:

Insulin Analog

Clinical Trials (5)

NCT05684341N/ACompleted

A Randomized Controlled Trial to Compare the Glycemic Control, With or Without the Connected Solution, of Adult Type 2 Diabetic Participants on Basal Insulin in Taiwan

Started Feb 2023
200 enrolled
Type 2 Diabetes Mellitus
NCT04678661N/ATerminated

My Dose Coach Mobile App to Support Insulin Titration and Maintenance

Started Feb 2021
60 enrolled
Diabetes Mellitus Type 2 - Insulin-Treated
NCT03903016Phase 1Completed

A Bioequivalence Study Comparing Two Different Strengths Formulations of Insulin Lispro in Patients With Type 1 Diabetes

Started Mar 2019
90 enrolled
Type 1 Diabetes
NCT03713684Phase 3Terminated

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)

Started Nov 2018
370 enrolled
Type 2 Diabetes Mellitus
NCT03436498Phase 1Completed

Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion for Type 1 Diabetes Mellitus Patients

Started May 2018
45 enrolled
Type 1 Diabetes Mellitus